A Phase 3 clinical trial, MOMENTUM, evaluating Axsome Therapeutics’ (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine met the co-primary endpoints compared to placebo.
The key secondary endpoint of demonstrating superiority to rizatriptan was also met.
AXS-07 consists of a rapid absorption extended half-life form of the NSAID meloxicam, enabled via the company’s MoSEIC (Molecular Solubility Enhanced Inclusion Complex) technology, combined with rizatriptan, a 5-HT1B/D agonist that narrows blood vessels.
Management hosted a conference call this morning at 8:00 am ET to discuss the results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.